<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; distribution</title>
	<atom:link href="http://www.tapanray.in/tag/distribution/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Covid Vaccine Challenges – Abidance To Defined Health Norms Stays As Lifeguard</title>
		<link>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard</link>
		<comments>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/#comments</comments>
		<pubDate>Mon, 16 Nov 2020 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abidance]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[immunization]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[norms]]></category>
		<category><![CDATA[program]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UIP]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10327</guid>
		<description><![CDATA[There isn’t even a shade of doubt today that Covid-vaccines are coming. However, some critical questions in this area continue to hang in the air, and are expected to remain so for some more time. Thus, every news on the &#8230; <a href="http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India Being World’s Third largest Covid Vaccine Maker: Will All Indians Benefit?</title>
		<link>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit</link>
		<comments>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/#comments</comments>
		<pubDate>Mon, 02 Nov 2020 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[all third]]></category>
		<category><![CDATA[ambiguity]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[Bihar]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[countrywide]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[election]]></category>
		<category><![CDATA[equitable]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indians]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[largest]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[maker]]></category>
		<category><![CDATA[manufacturer]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[Nationalism]]></category>
		<category><![CDATA[oxfam]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Serum Institute of India]]></category>
		<category><![CDATA[SII]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uninterrupted]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[virus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10311</guid>
		<description><![CDATA[Apprehensions on the time of availability notwithstanding, equitable access to Covid vaccines for all, remain the best hope to leash the deadly virus, as the pandemic overwhelms the world. According to the World Health Organization (WHO) ‘Coronavirus Update 37’ of October 06, &#8230; <a href="http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-being-worlds-third-largest-covid-vaccine-maker-will-all-indians-benefit/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Free Medicines In, Would The New Government Revisit ‘Universal Health Coverage’ Soon?</title>
		<link>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon</link>
		<comments>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/#comments</comments>
		<pubDate>Mon, 02 Jun 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[consulting]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Manmohan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OP]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[Rajasthan]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tamil Nadu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[Vardhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5462</guid>
		<description><![CDATA[Friday last, the new Union Health Minister Dr. Harsh Vardhan reportedly announced that the his ministry would soon start work on distributing free medicines through public hospitals across the country. For this purpose the Minister would soon call a meeting of the &#8230; <a href="http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>After Mollycoddling China Cracks Down on Pharma MNCs&#8230;But Why Now?</title>
		<link>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now</link>
		<comments>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/#comments</comments>
		<pubDate>Mon, 22 Jul 2013 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[aeon]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Anathema]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Chen]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[clampdown]]></category>
		<category><![CDATA[contaminated]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[crackdown]]></category>
		<category><![CDATA[Danone]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Dragon]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[enforced]]></category>
		<category><![CDATA[exemplary]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grip]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[hazards]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[land]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[meat]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[mollycoddling]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[powder]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[principle]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rat]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[staggering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tightening]]></category>
		<category><![CDATA[violations]]></category>
		<category><![CDATA[Zu]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2948</guid>
		<description><![CDATA[In tandem with exemplary growth in the healthcare sector, China has started confronting with some consequential hazards in form of serious regulatory violations involving, besides many others, hospitals, pharmaceutical pricing and food and drug safety, which reportedly include contaminated milk powder and &#8230; <a href="http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing in India: 10 Chain Events to Catalyze a Paradigm Shift</title>
		<link>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift</link>
		<comments>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/#comments</comments>
		<pubDate>Mon, 17 Jun 2013 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alibaba]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[cocoon]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[composite]]></category>
		<category><![CDATA[Cosmetic]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[differentiated]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[faster]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herald]]></category>
		<category><![CDATA[Heralding]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[ICICI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Lombard]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[mediclaim]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of pharma]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmacy-economics]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[remedies]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transition]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[well]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2454</guid>
		<description><![CDATA[In the matured markets of the world pharmaceutical marketing is quite different in many respect as compared to India. Besides doctors, different sets of customer groups like, healthcare providers, patient advocacy groups, pharmacy benefit managers, clinical assessment authorities play various &#8230; <a href="http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-in-india-10-chain-events-to-catalyze-a-paradigm-shift/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Government Ups the Ante for More Compulsory Licenses in India</title>
		<link>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=government-ups-the-ante-for-more-compulsory-licenses-in-india</link>
		<comments>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/#comments</comments>
		<pubDate>Mon, 21 Jan 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[deficiencies]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[nurses]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[skewed]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[third]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[uncertainty]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1442</guid>
		<description><![CDATA[On January 12, 2013, one of the leading dailies of India first reported that in a move that is intended to benefit thousands of cancer patients, Indian Government has started the process of issuing Compulsory Licenses (CL) for three commonly &#8230; <a href="http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Maintaining Supply Chain Security in pharmaceuticals: The need is now more than ever before.</title>
		<link>http://www.tapanray.in/maintaining-supply-chain-security-in-pharmaceuticals-the-need-is-now-more-than-ever-before/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maintaining-supply-chain-security-in-pharmaceuticals-the-need-is-now-more-than-ever-before</link>
		<comments>http://www.tapanray.in/maintaining-supply-chain-security-in-pharmaceuticals-the-need-is-now-more-than-ever-before/#comments</comments>
		<pubDate>Mon, 26 Sep 2011 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[before]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[ever]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[Maintaining]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[now]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=197</guid>
		<description><![CDATA[In today’s globalized economy maintaining Supply Chain Security (SCS), especially in the pharmaceutical sector across the world, is more critical than ever before. We have many instances of SCS being seriously breached, not only in the emerging pharmaceutical markets but &#8230; <a href="http://www.tapanray.in/maintaining-supply-chain-security-in-pharmaceuticals-the-need-is-now-more-than-ever-before/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maintaining-supply-chain-security-in-pharmaceuticals-the-need-is-now-more-than-ever-before/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Jan Aushadhi’ – ‘Medicines for the common man’ project of DoP is a great idea – is it on course?</title>
		<link>http://www.tapanray.in/jan-aushadhi-medicines-for-the-common-man-project-of-dop-is-a-great-idea-is-it-on-course/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=jan-aushadhi-medicines-for-the-common-man-project-of-dop-is-a-great-idea-is-it-on-course</link>
		<comments>http://www.tapanray.in/jan-aushadhi-medicines-for-the-common-man-project-of-dop-is-a-great-idea-is-it-on-course/#comments</comments>
		<pubDate>Mon, 23 Mar 2009 01:30:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[course]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[great]]></category>
		<category><![CDATA[idea]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Jan-Aushadhi]]></category>
		<category><![CDATA[man]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=935</guid>
		<description><![CDATA[In mid 2008 The Government of India created a new department, ‘The Department of Pharmaceuticals’ (DoP), under the Ministry of Chemicals and Fertilisers. The new department came out with its following vision statement:“To enable Indian pharmaceuticals industry to play a &#8230; <a href="http://www.tapanray.in/jan-aushadhi-medicines-for-the-common-man-project-of-dop-is-a-great-idea-is-it-on-course/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/jan-aushadhi-medicines-for-the-common-man-project-of-dop-is-a-great-idea-is-it-on-course/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
